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research has been carried out on reptile venom,mammalian venomhas been poorly studied
to date. Here we describe the status of current research into the venom of the platypus, a
semi-aquatic egg-laying Australian mammal, and discuss our approach to platypus venom
transcriptomics. We propose that such construction and analysis of mammalian venom
transcriptomes from small samples of venom gland, in tandem with proteomics studies,
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studies and pharmacological evaluation of the identified toxins will then lay the
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useful molecules have already been identified in snake venom, and many of these are
currently in use in humanmedicine. It is therefore hoped that this basic research to identify
the constituents of platypus venom will eventually yield novel drugs and new targets for
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The platypus (Ornithorhynchus anatinus) is an Australian
monotreme with a plethora of unusual features stemming
from the position of the monotremes as the earliest extant
offshoot from the mammalian lineage. One of the most
interesting traits of the platypus is that the male of the
species is venomous. Venom in a mammal is extremely
unusual: only four other species of mammal are known to be
venomous, and these all fall within the order Insectivora
(shrews and hedgehogs) [1].
Despite the fact that venom in a mammal is remarkable,
and that it may contain biomedically useful substances, our
knowledge of platypus and Insectivore venom is incomplete.
Here we review current knowledge of platypus venom and
discuss our plans for future work. It is hoped that, through the
construction and analysis of venom transcriptomes, we will
discover the contents and unravel the evolutionary history of
mammalian venom.2. Platypus venom and the crural system
The venom apparatus in the platypus is known as a crural
system. It consists of a venom gland on the dorsocaudal side
of the abdomen, which is connected via a venom duct to the
spur on each hind leg [2] (Fig. 1). Juvenile females possess a
remnant spur sheath that is subsequently lost during the first
year of life, and spurs develop only in males [2]. The gland is
thought to migrate during male development from the inner
surface of the thigh to the dorsocaudal surface [3]. At
maturity, during the spring breeding season, the venom
gland increases to peak size (in parallel with increases in
testis size) and venom production increases [3].Fig. 1 –Schematic drawing indicating the approximate pThe exact function of the platypus crural system is
unclear. A significant number of platypuses are killed by
foxes and dogs, but the platypus has few native predators
(crocodiles, Tasmanian devils and raptors have been
observed preying on platypuses) [2,4]. This, combined with
the fact that the venom gland increases in size during the
breeding season, suggests that the crural system may have
evolved to have a reproductive rather than defensive func-
tion. Whatever the original function of platypus venom was,
at present the crural system can be used as an effective
defence mechanism against potential predators (for example
humans and domestic dogs), and it may also be used as an
offensive weapon to assert dominance over other male
platypuses during the breeding season [2].
Envenomation occurs when the platypus wraps both hind
legs around the victim, driving the spurs into the flesh, and in
humans, assistance is often needed to disengage the attacking
platypus, as it is able to support its full weight by its spurs [5]. Up
to 4 ml of venom is available to be injected each time [3].
However, in practice, it is difficult to obtain anything close to this
amount when collecting venom in the field. We have found that
the central channel of the spur of an adult male platypus has a
diameter of∼0.2mm (Fig. 2), andwhenwe attempted delivery of
aqueous solution through this small aperture, it required many
seconds under high pressure to achieve 4 ml. When we have
acquired samples that have been collected in the field, volumes
of the order of 100 µl have usually been obtained.
Platypus envenomation has been known to kill dogs (in the
days when retrievers were used to recover platypuses during
hunting) [e.g. [6]], but the trapping of male animals with
healed spur marks suggests that envenomation by their own
species is not usually fatal [2]; in one case it was observed that
envenomated male platypuses displayed oedema and tem-
porary paralysis of spurred limbs [3]. It has been proposed thatosition of the platypus venom gland and erect spur.
Fig. 2 –Photograph of spur of adult male platypus. A wire of
0.1 mm diameter is inserted through the central channel of
the spur (two of these wires can fit through the central
channel at once). Scale: marks on the ruler at the base are
1 mm apart.
157J O U R N A L O F P R O T E O M I C S 7 2 ( 2 0 0 9 ) 1 5 5 – 1 6 4envenomation of other platypuses confers an advantage to
dominant males by causing pain and inhibition of locomotion
in rivals, in order to leave the dominantmale at liberty tomate
without having to fight many times.3. The contents of platypus venom
Although human fatalities due to platypus envenomation
have never been reported, the venom does produce swelling
and immediate and excruciating pain, which cannot be
relieved through normal first-aid practices [5], as well as
nausea, gastric pain, cold sweats and lymph node swelling [3].
Even morphine is reported to be mostly ineffective as an
analgesic [5]. In one of the few cases of platypus envenoma-
tion recorded in detail, clinical pathology revealed a high
erythrocyte sedimentation rate and low total serum protein
and albumin levels. The patient also reported generalised
‘whole body’ pain, localised pain that persisted for several
weeks after envenomation, and he also experienced signifi-
cant muscle wasting of the affected forearm [5].
The unusual symptoms of platypus envenomation suggest
that platypus venom may contain clinically useful and poten-
tially novel substances, but our knowledge of platypus venom is
incomplete. The venom is known to consist of at least nineteen
different peptide fractions along with non-peptide components
[7,8]. To date, only three types of peptides have been identified
and fully sequenced: C-type natriuretic peptides (OvCNPs),
defensin-like peptides (OvDLPs), and nerve growth factor
(OvNGF), and their exact functions are not yet known [9,10]. A
venom peptide isomerase and hyaluronidase have also been
discovered, but their full sequences have not been determined
[7], and the venom is also known to have protease activity [7].Fig. 3 –A schematic drawing of DLP-1; 20 different possible
structures are overlain as determined by NMR. The location
of the 310 helix (red and yellow) and β-strands (cyan) is
shown [11]. The figure was constructed using MOLMOL [44].4. Proteomic studies of platypus venom
The starting point for the identification of the existing compo-
nents of platypus venom was with the availability of proteincharacterisation techniques. The reverse-phase HPLC chromato-
gram of platypus venom reveals many novel polypeptides
ranging in size from 4 to 6 kDa [11–13] and proteins with sizes
above 12 kDa. Four of thosementioned above have been isolated
and studied, including the OvDLPs, OvCNPs, OvNGF, and the
peptide isomerase.
4.1. Ornithorhynchus venom defensin-like peptides
(OvDLPs/DLPs)
The OvDLPs are four polypeptides of ∼5 kDa, so named because
one of these polypeptides, DLP-1, was found in earlier studies to
have a three-dimensional fold very similar to that of β-defensin-
12 [14,15], a member of the β-defensin-fold family of polypep-
tides. This peptide family is found in a diverse array of organisms
such as sea anemones, snakes, and humans [16]. β-defensins are
∼35–50 amino acid residues in length, and are generally
characterised by a short helix, followed by a small twisted anti-
parallelβ-sheet. They contain six cysteine residues (pairing in the
sequence pattern 1–5, 2–4 and 3–6), which are crucial for
maintaining the compact central core [16].
Studies of OvDLPs at both a gene [10,17] and protein [e.g.
[11,12]] level have been carried out. The proteinDLP-1 is coded for
by OvDLP-C, and the protein DLP-2 (and DLP-4, a post-transla-
tionally modified form of DLP-2) is coded for by OvDLP-B. The
gene coding for DLP-3 has not been identified, although the
amino acid sequence of this peptide is very similar to that of DLP-
2. In addition, another OvDLP gene (OvDLP-A) has also been
identified.
It is believed that in the β-defensins the global fold is robust,
and the biological function is determined by the nature of the
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diverse biological activities, including antimicrobial, ion-channel
inhibiting, myonecrotic, and analgesic activities [16]. However,
the OvDLPs have no antimicrobial or ion-channel activity, so
their exact function is a mystery [11]. It is hypothesised that
since they are the most abundant peptides in the venom, the
OvDLPs may contribute to the production of the pain that is
characteristic of platypus envenomation [12,16].
4.2. DLP-1
In DLP-1 (coded for by theOvDLP-C gene [10]), residues 15–18 and
37–40 form an anti-parallel β-sheet, and residues 10–12 form a
short 310 helix (Fig. 3). It is also possible that residues 7–8 and
residues 30–31 form a short parallel β-sheet. The short 310 helix
and the anti-parallel β-sheet are connected by residues 13–14.
The two anti-parallel β-strands are twisted and connected by a
large loop encompassing residues 19–36, which contains a series
of turns [11]. A well-defined hydrophobic region comprising
residues Cys-9, Ile-12, Ile-27, Phe-28, Leu-29, Ala-30 and Cys-39 is
present in DLP-1. Side chains of Ile-12, Ile-27 and Ala-30 form the
central core, while the side chains of Phe-28 and Leu-29 are
oriented away and exposed to the aqueous solvent. DLP-1 has 10
positively charged residues and six negatively charged ones.
While the cationic residues are concentrated in three regions of
the molecule, the basic residues do not form a cluster [11].
4.2.1. DLP-2 and DLP-4
The42 residuesofDLP-2 (coded for by theOvDLP-Bgene [10]) have
36%sequencesimilaritywithDLP-1 [11].Thesixcysteine residues
are spaced in the sequence in a similarmanner in both peptides,
and the 14–17 and 37–40 amino acid stretches, which incorporateFig. 4 –A schematic drawing of DLP-4 (A) and DLP-2 (B); 20 differen
location of α-helix (red and yellow) and β-strands (cyan) is showmost of the anti-parallel β-strands, are also seen in both DLP-1
andDLP-2 [11]. It can be seen in Fig. 4 that DLP-2 has a short helix
formed by residues 9–12 and an anti-parallel β-sheet formed by
residues 15–18 and 37–40. Residues 13–14 connect thehelix to the
first anti-parallel β-strand. The anti-parallel β-sheet is twisted
and connected by a large loop, formed by residues 19–36, that
surrounds the second β-strand and has four β-turns [11]. The
C-terminus is bent near residue 41 and points towards the
firstβ-strand. TheN-terminushas a large regionof hydrophobic
residues, and the side chains of these residues are oriented
towards the surface and exposed to the aqueous solvent. DLP-2
also has two highly charged hydrophilic regions, one encom-
passing part of the first β-strand and two β-turns and the other
at the end of the large loop encompassing one β-turn [12].
DLP-4 has an identical amino acid sequence to and the
same molecular mass as DLP-2, and the only apparent
difference between the two peptides is that that they elute
at different retention times in reverse-phase HPLC. The reason
for this was a mystery until recently, when it was shown that
DLP-2 has a D-amino acid residue at position 2 of its sequence,
thus accounting for the HPLC effect [18]. Fig. 4 shows that both
peptides are folded in the same way, as both have the same
amino acid sequence.
4.3. Ornithorhynchus venom C-type natriuretic peptides
(OvCNPs)
The OvCNPs have high sequence similarity to themammalian
C-type natriuretic peptides, which are characterised by having
two cysteines paired together to form a 17-residue loop. The
loop can be either A-, B- or C-type, and this is defined by the
nature of the terminal extensions beyond the loop [19].t possible structures are overlain as determined by NMR. The
n [12]. These figures were constructed using MOLMOL [44].
Fig. 5 –Schematic drawings of OvCNPa in (A) aqueous
solution and (B) SDS micelles, showing the orientations of
side chains. Chains are coloured as follows: hydrophobic
(yellow), cationic (blue), anionic (red) and OH-containing
(green) [22]. These figures were constructed using MOLMOL
[44].
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active, having been found to relax rat uterine smooth muscle,
and promote oedema and mast cell histamine release
[7,20,21]. They can also form ion channels in lipid bilayer
membranes [8]. Like DLP-2/4, OvCNP can exist in two isomeric
forms (OvCNPa and OvCNPb) [22]. Both have identical amino
acid sequences but have different retention times upon
elution from reverse-phase HPLC; OvCNPb has a D-amino
acid residue at the second position from the N-terminus [23].
Fig. 5 shows the structures of OvCNPa in aqueous solution
and SDS micelles. The linear portion of OvCNPa does not have
a hydrophobic core, while the cyclic portion has a distinct
hydrophobic region centred on the side chain of Phe-24 [22].
This region is important in maintaining the structure of the
cyclic portion and is flanked by the side chains of Leu-26, Leu-
28, Leu-37, Cys-23 and Cys-39. The fold at the N-terminal
extension in OvCNPa has an extended configuration in
aqueous solution compared to itsmore compact configuration
in SDSmicelles. Both configurations show a β-turn at residues
25–28, but there are significant structural differences in the
cyclic portion of the peptide when it is dissolved in the two
solvents. The hydrophobic core is present at the centre of the
cyclic portion in aqueous solutions, but is absent in SDS
micelles; in SDS micelles the disulphide bond between
residues 23 and 39 is more extended than in aqueous solution
[22]. These differences are determined by the different
orientation or nature of turns within the peptide.
4.4. Ornithorhynchus nerve growth factor (OvNGF)
The nerve growth factor protein isolated from platypus venom
(OvNGF) is 13 kDa in size [12]. Nerve growth factor (NGF) is
found in a variety of snake venoms. It is hypothesised that
NGF from snake venoms may increase the effects of other
venom toxins by stimulating various cells in the victims, thus
rendering them more susceptible to the effects of envenoma-
tion [12]. In humans, NGF can cause hyperalgesia [24]; it is
noted that hyperalgesia is one of the symptoms associated
with platypus envenomation. To date, OvNGF has not been
studied in detail. Interestingly, in reverse-phase HPLC, OvNGF
is co-eluted with DLP-3. It is thus possible that the protein
might act synergistically with DLPs to produce the pain that is
typical of platypus envenomation [12]. It is also possible that
OvNGF might have a very similar function to snake venom
NGF, but this has not yet been investigated.
4.5. Peptide isomerase
The fact that DLP-2 and OvCNPb both exist in isomeric forms
containing a D-amino acid at the second position is very
significant. D-amino-acid-containing peptides are more stable
in tissues, less prone to protease degradation [25–27], and some
D-amino-acid-containing peptides in animals and insects are
more potent than their L-form counterparts [28]. For example,
dermorphin, a heptapeptide containing D-alanine in the second
position, isolated from the skin of the South American tree frog
(Phyllomedusa sauvagei), is one thousand times more potent than
morphine at inducing analgesiawhen injected into the brain [29].
The existence of D-amino-acid-containing peptides in
platypus venom suggested the presence of an isomerase thatis responsible for the interconversion between the isomeric
peptides. In 2005, a platypus venom peptide isomerase (also
known as L-to-D-peptide isomerase) of ∼50–60 kDa was
discovered [18]. It is the first such enzyme to be reported in a
mammal and is likely to be physiologically important, because
OvDLPs are the most abundant peptides in the venom and
OvCNPs have potent physiological activity. The peptide
isomerase acts on the second amino acid residue from the
N-terminus and operates in both directions of the reaction
(L-to D-and D-to L-) [30]. The structure of this enzyme has not
yet been solved, but a proposed model of its active site was
generated based on its substrates (Fig. 6).
Fig. 6 –Proposed model of the active site of the peptide isomerase. The first three amino acid residues of (A) DLP-4 (IMF) and (B)
DLP-2 (ImF) are modelled; the tripeptides are arranged in the same coordinate system with respect to the benzyl-group of
phenylalanine [30]. Models were constructed using RasMol [45].
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active on two 12-residue peptides (IMFFEMQsrsrs and
ImFFEMQsrsrs), which were derived from the 7-residue N-
terminal segments of DLP-4 and DLP-2, with a solubilising
peptide (srsrs) added to the C-terminus [25]. A more recent
study of the substrate specificity used synthetic hexapeptides,
with the first three amino acid residues derived from the N-
terminus of OvDLPs and OvCNPs, followed by a short
solubilising peptide (srs) [30]. The analogues of DLP-4 and
DLP-2 (IMFsrs and ImFsrs, respectively) and the synthetic
hexapeptides that incorporate L-/D-norleucine and L-/D-phe-
nylalanine as the second amino acid residue were found to be
the active substrates [30]. In carrying out peptide isomerase
assays, the hexapeptide INleFsrs is the preferred substrate,
because its isomerisation is the fastest and the peptide is less
prone to degradation compared to the methionine-containing
DLP-4 analogue. The hexapeptide analogues of OvCNPa and
OvCNPb (LLHsrs and LlHsrs, respectively) do not act as
substrates [30], so the full-length chain appears to be required
to make the N-terminus a substrate. It is clear that the peptide
isomerase is active on shorter peptides with at least three N-
terminal amino acid residues in which the second amino acid
residue has a long hydrophobic side chain while the thirdFig. 7 –Proposed two-base mechanism for the action of the pepti
and the reprotonation of the opposite face by the histidyl base [3amino acid residue must be aromatic, either phenylalanine or
histidine [30].
The platypus venom peptide isomerase is inhibited by
amastatin, which suggests that histidine residues are present
in or near the active site [25,30]. Preliminary results have
shown that two histidine residues are encoded in the central
portion of the candidate peptide isomerase gene (unpublished
data). A two-base mechanism has been proposed for the
isomerisation [30]. In this model, two histidine residues are
positioned on the opposite sides of the substrate. One
deprotonates one face of the α-carbon of the second amino
acid residue and forms a planar intermediate, while the other
(in its conjugate acid form) reprotonates the opposite side of
the α-carbon and forms the stereo-inverted product (Fig. 7).
The gene coding for DLP-2/DLP-4 (OvDLP-B), which is
acted on by the peptide isomerase, is expressed in platypus
tissues including brain, intestine, kidney, lung, spleen and
testis [17], which raises the possibility that the isomerase is
also expressed here and that it might be expressed in higher
mammals. This idea was confirmed by recent work, which
has revealed the existence of the peptide isomerase in
platypus tissues other than the venom gland (unpublished
data).de isomerase. The deprotonation of one face of the α-carbon
0].
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We know very little about mammalian venom. While a basic
search of the Web of Science Database (ISI Web of Knowledge,
Thomson Reuters, 11th November 2008) using the search term
‘“reptile venom” OR “snake venom”’ yields 4282 hits, a search
of the same database using ‘“mammalian venom” OR “platy-
pus venom” OR “shrew venom”’ yields just 34.
The many biomedically useful compounds that have been
obtained from reptile venom suggest that the dearth of
mammalian venom studies is not due to a lack of utility of
this kind of research. One reason may be that reptile venoms,
which cause significant numbers of human fatalities, have
received research priorities because of the scope for the
development of antivenins and also because they are seen
as more toxic than mammalian venom. Another important
cause is the very limited quantity of mammalian venom
available for study [31]. Snake venom from many different
species is available in reasonable quantities from research
colonies which produce venom year-round [e.g. [32]]. Platypus
venom, on the other hand, is quite difficult to obtain. It must
be milked, which involves a certain amount of risk to the
researcher, it is only obtained in small quantities, and only
half of adult animals (the males) produce it. Furthermore, it is
not possible to obtainmany samples from captive individuals.
Platypuses have been difficult to breed in captivity [33],
meaning that they are generally left undisturbed during the
breeding season [34] in order to maximise the chances of
breeding success. To obtain venom samples, it is therefore
generally necessary to capture animals in the wild, which is a
difficult and time-consuming process.
Insectivore venom is also extremely difficult to sample.
Most of the venomous insectivores are very small, and so
produce low venom yields [35]; for example, a single specimen
of one Insectivore (Neomys foydens) yields only 200 mg of
venom gland tissue, meaning that obtaining enough venom to
do a comprehensive protein purification studywould probably
decimatewild populations [1], and in addition some species (e.
g. Solenodon) are endangered. The animals are also extremely
difficult to capture alive and keep in captivity, meaning that
repeated venom collections are impossible [1].
In short, purification and then characterisation of the
components of platypus and Insectivore venom are extremely
difficult to do at a protein level alone, given the small amounts
of venomavailable. For example, it took 1–2ml of crude venom
to identify OvDLP, OvCNP, and OvNGF in platypus venom.
Therefore, we suggest, like others before us [1], that the best
(and perhaps only) way for research into the components and
action of mammalian venom to progress will be through
genomic studies, primarily the identification and character-
isation of venom genes from venom transcriptomes.6. The platypus venom transcriptome
As a first case study, we are constructing and analysing a
platypus venom transcriptome (cDNA library) to identify the
subset of genes that are active in venom glands. This means it
will be possible to identify all of the platypus venomcomponents from a single venom gland by examining the
products of the expressed genes. We have obtained a venom
gland from an adult male that was killed during the breeding
season by a domestic dog. From this, total RNA was extracted
and we have constructed a venom gland cDNA library, which
is currently undergoing sequencing on Next-Generation
platforms.
6.1. Separating venom genes from genes coding for normal
cellular processes
Traditionally, EST sequencing projects are treated as large-
scale annotation projects; for each read (or contiguous
sequence [contig]), BLAST (Basic Local Alignment Search
Tool) or a similar alignment tool is used to identify known
proteins that are similar. A potential hurdle to the identifica-
tion of the full range of platypus venom genes from a venom
gland transcriptome is the need to separate genes whose
products have toxin function from genes coding for normal
cellular processes. As the platypus is separated from other
mammals by a large evolutionary distance (monotremes
diverged from the mammalian lineage 166 million years ago
[9]), it is difficult to identify orthologues by simply searching
the NCBI GenBank database (http://www.ncbi.nlm.nih.gov/)
with the transcriptome read data using BLAST. The fact that
many venom genes in other species have been shown to have
evolved from genes coding for normal cellular products [36]
also means that it is difficult to reject an expressed gene as a
venom component just because it has some homology with a
gene coding for a protein involved in a ‘conventional’ cellular
process.
The approach taken in several snake venom sequencing
projects has been to assemble sequence information into contigs
and then to search contigs against the GenBank database, using
anE-value cut-off to separate toxinandcellular functioninggenes
[e.g. [37,38]]. It is then possible to classify the toxin genes into
functional groups according to the sequences with which they
share strong homology. This approach works well because there
are a multitude of venomous snake species, and the venom of
some of them has been well-studied, though truly novel
components may still be missed. This means that there are a
large number of snake venom sequences from reasonably close
relatives available to search; ToxProt, a database of animal toxins
(http://ca.expasy.org/sprot/tox-prot/), contains 1060 reptilian
venom sequences at present (11th November 2008). Clearly this
is not the case for venomous mammals; the ToxProt database
contains only seven mammalian toxin sequences (11th Novem-
ber 2008).
6.2. Our approach
The availability of the platypus genome [9] provides us with an
additional resource for transcriptomic studies including a pre-
dicted gene build and framework for discovering novel venom
proteins. To make use of these, we will map platypus venom
transcriptome data to the platypus genome and examine over-
lapping Ensembl gene predictions (http://www.ensembl.org/
Ornithorhynchus_anatinus/Info/Index), and where there are no
annotated genes, construct our own gene predictions in the area
of each read hit.
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many venom gland transcripts as possible in order to identify
putative functions [39]. We have previously shown that all of
the platypus venom genes for which we currently have
sequence have homologues in reptile venom, and we have
suggested that there are specific classes of proteins that are
preferentially selected during the evolution of venom proteins
[10]. Therefore, we anticipate that many of the newly
identified platypus venom genes will also have reptilian
venom homologues. We will also be seeking to link toxin
gene annotation to these platypus venom transcripts using
BLASTs against the ToxProt (http://ca.expasy.org/sprot/tox-
prot/) and ATDB [40] databases. In this way, we hope to be able
to start the preliminary toxin classification to a number of
genes that are expressed in the platypus venom gland.
Since platypus and reptile venoms have evolved separately
[10], it is possible that some components of the venom will be
completely novel and be unannotated by Ensembl or have no
predicted function and have no homologues in ToxProt. These
novel platypus venom components may be the most interest-
ing outcomes of the transcriptome project, as they may have
functions that have not been observed in any other venoms to
date. This also means that they may be the most promising
candidates for the development of novel drugs.
At the time of library construction and sequencing only a
single venom gland obtained from a male during the breeding
season (which was therefore producing large amounts of
venom) was available, and no juvenile or out-of-season gland
was available. Consequently, it was decided to normalise the
cDNA library. This had the advantage of increasing the
chances of detecting rare (lowly expressed) venom gland
transcripts, and made the sequencing coverage of transcripts
more uniform, thereby improving the transcript assembly
quality and also providing a resource to improve the annota-
tion of the genome in general. However, it was at the expense
of expression abundance information on each gene, which
could hold some clue as to the importance of each transcript in
venom. In the future, we plan to explore transcript abundance
through the use of unnormalised cDNA from contrasting
venom-producing and non-venom producing glands using
microarrays or RNA-seq. In particular, genes that are differ-
entially expressed between the breeding and non-breeding
season venom glands will play critical roles in venom. The
seasonal nature of platypus venom makes platypus some-
thing of a special case for transcriptomics and affords us the
opportunity to use differential expression analysis to find
venom genes. More generally, whether to initially normalise
cDNA libraries from mammalian venom glands and rely only
on homology, or to not normalise and utilise within-tissue
abundance information, is an important experimental design
decision. Regardless, final validation of putative toxin proteins
will require the appropriate in vitro and in vivo assays.
Once putative toxin transcripts have been identified, they can
thenbe synthesised as peptides in vitro or expressedasprotein in
cells to study their biological effects. It is recognised that some
proteinswill notbe in thecorrectpost-translational conformation
and some will be beyond current protein synthesis capabilities
due to their size.Nevertheless, wepropose that this approachwill
be very informative toward defining the biological properties of
mammalian venom proteins.Proteomics studies will be carried out in tandem with our
transcriptome evaluation. By comparing the protein expression
profiles of the platypus venom gland obtained during the
breeding season and the non-breeding season, we can identify
the proteins that are expressed uniquely during the breeding
season and collate this data with the differential RNA expres-
sion data from transcriptomes. Protein identification can be
done by the combined use of two-dimensional gel electrophor-
esis and mass spectrometry; first to explore the differences in
protein expression levels using two-dimensional gel electro-
phoresis, and then spot identification of proteins by mass
spectrometry. This work is currently in progress.
6.3. The importance of studying platypus and other
mammalian venoms
This work on platypus venom will be followed by a similar
shrew venom transcriptome project. Identification of the
components of both platypus and shrew venoms would
provide insight into the mechanisms of the evolution of
mammalian venom and the reasons why it is a comparatively
rare trait.
The utility of mammalian venom transcriptome projects
should also extend to having human benefits. An under-
standing of mammalian venoms may improve knowledge of
intra-and intercellular signalling in mammals. For example,
further research into the platypus venom peptide isomerase
may lead to its identification in higher animals including
humans, where D-amino acids possibly participate in the
aetiology of altered-protein-turnover diseases like Alzhei-
mer's and amyloidosis [41].
Another promising benefit that may come from mamma-
lian venom research is the discovery of novel therapeutic
agents. Snake venoms have already been used in many
pharmaceutical applications [42]. The identification of mam-
malian venom components will allow their synthesis and
subsequent functional characterisation, and it is anticipated
that this will provide another rich source of newmolecules for
pharmaceutical design. For example, given that D-amino-acid-
containing peptides and proteins are more stable in vivo,
medically useful therapeutic peptides with greater stability in
vivo may eventuate from platypus venom peptide isomerase
research. In fact, despite the dearth of mammalian venom
research to date, there is already a patent for the use of
soricidin (a shrew venom peptide) as an analgesic, a wrinkle
treatment, a mechanism to immobilise muscles to treat
neuromuscular diseases, and a treatment for excessive
sweating [43]. The unusual symptoms of platypus envenoma-
tion suggest that platypus venom contains many unique
substances which may also be clinically useful. In particular,
we are interested to identify the toxin that causes the extreme
pain. It is possible that this could lead to the discovery of new
human pain receptors and thus targets for painkillers.
In conclusion, the constructionand sequencing of a platypus
venom gland cDNA library, used in combination with the
recently sequenced platypus genome [9], promises to be an
efficient means of discovering new venom genes. Complemen-
tary studies in genomics and proteomics have the potential to
substantially increase our knowledge of mammalian venoms.
We anticipate that this will allow the identification of the
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further investigations of mammalian venom in general, func-
tional studies, and the development of novel pharmaceuticals.Acknowledgements
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